FDA Joint Reviews Would Benefit From Early Collaboration Meetings – Lewin
This article was originally published in The Gray Sheet
FDA should rely increasingly on early collaboration meetings in the review of combination products, according to the fourth in a series of reports prepared by The Lewin Group health care consultant for AdvaMed
You may also be interested in...
Preclinical studies of drug-eluting stents should include overdose testing to ensure the safety of overlapping stents, FDA review staff advises
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.